WO2011143128A3 - Multi-phasic nanostructures for imaging and therapy - Google Patents

Multi-phasic nanostructures for imaging and therapy Download PDF

Info

Publication number
WO2011143128A3
WO2011143128A3 PCT/US2011/035779 US2011035779W WO2011143128A3 WO 2011143128 A3 WO2011143128 A3 WO 2011143128A3 US 2011035779 W US2011035779 W US 2011035779W WO 2011143128 A3 WO2011143128 A3 WO 2011143128A3
Authority
WO
WIPO (PCT)
Prior art keywords
imaging
therapy
disclosure
composites
phasic
Prior art date
Application number
PCT/US2011/035779
Other languages
French (fr)
Other versions
WO2011143128A2 (en
Inventor
Xiaohu Gao
Shang-Hsiu Hu
Original Assignee
University Of Washington Through Its Center For Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington Through Its Center For Commercialization filed Critical University Of Washington Through Its Center For Commercialization
Publication of WO2011143128A2 publication Critical patent/WO2011143128A2/en
Publication of WO2011143128A3 publication Critical patent/WO2011143128A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Treatment Devices (AREA)

Abstract

Aspects of the disclosure are directed to nano-scale composites with spatially separated functionalities such as for imaging probe engineering and therapeutic formulations. Additional aspects of the disclosure are directed to magnetic field modulated imaging and therapies. Included in the disclosure is the use of the composites for magnetolytic therapy, whereby cell lysis is effected by impacting magnetic composites into a cell using a spinning or oscillating magnetic field.
PCT/US2011/035779 2010-05-10 2011-05-09 Multi-phasic nanostructures for imaging and therapy WO2011143128A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33324410P 2010-05-10 2010-05-10
US61/333,244 2010-05-10
US33366010P 2010-05-11 2010-05-11
US61/333,660 2010-05-11

Publications (2)

Publication Number Publication Date
WO2011143128A2 WO2011143128A2 (en) 2011-11-17
WO2011143128A3 true WO2011143128A3 (en) 2012-03-29

Family

ID=44914925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035779 WO2011143128A2 (en) 2010-05-10 2011-05-09 Multi-phasic nanostructures for imaging and therapy

Country Status (1)

Country Link
WO (1) WO2011143128A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8701471B2 (en) 2009-07-08 2014-04-22 University of Washington through its Center for Commercialiation Method and system for background suppression in magneto-motive photoacoustic imaging of magnetic contrast agents
CN104655836B (en) * 2013-11-25 2017-04-26 国家纳米科学中心 Immunochromatographic test strip, detection method by using immunochromatographic test strip, and application of immunochromatographic test strip
WO2022246058A1 (en) * 2021-05-21 2022-11-24 University Of Washington Partial endosomal magnetolysis for cytosolic delivery of biologics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020005145A1 (en) * 1999-12-13 2002-01-17 Jonathan Sherman Nanoparticulate titanium dioxide coatings, and processes for the production and use thereof
US20030175004A1 (en) * 2002-02-19 2003-09-18 Garito Anthony F. Optical polymer nanocomposites
US20070298257A1 (en) * 2006-06-23 2007-12-27 Florian Niklas Ludwig Nanoshells on polymers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020005145A1 (en) * 1999-12-13 2002-01-17 Jonathan Sherman Nanoparticulate titanium dioxide coatings, and processes for the production and use thereof
US20030175004A1 (en) * 2002-02-19 2003-09-18 Garito Anthony F. Optical polymer nanocomposites
US20070298257A1 (en) * 2006-06-23 2007-12-27 Florian Niklas Ludwig Nanoshells on polymers

Also Published As

Publication number Publication date
WO2011143128A2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
WO2013009595A3 (en) Injectable cns-derived ecm for tissue reconstruction
MX2014002087A (en) Pyrethroid formulations.
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MX366318B (en) Heterocycle amines and uses thereof.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PT3042910T (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
IN2015DN03219A (en)
WO2012154885A3 (en) Carbonic anhydrase targeting agents and methods of using same
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2015003352A (en) A whole, leech saliva extract.
ME02672B (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
PL2707010T3 (en) Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia
WO2013117744A3 (en) Methods of treating fibrosis
IL260078B (en) Therapy for use for the treatment of gaucher's disease
WO2012151242A3 (en) Lignin-based nanostructures
WO2012040331A3 (en) Multistage nanoparticles
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
WO2011143128A3 (en) Multi-phasic nanostructures for imaging and therapy
PL2859092T3 (en) Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1
WO2014072720A3 (en) Cell differentiation
WO2015079415A9 (en) Amorphous cobicistat solid dispersion
WO2012169345A3 (en) External skin preparation and production method of same
Brown et al. Introduction to Mplus: Practical sessions
Klimczak A Letter from Civil Association the “House of Poland” to CAFIU

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11781090

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11781090

Country of ref document: EP

Kind code of ref document: A2